BridgeMD
Searching for the right dose of perineural dexmedetomidine for a interscalene plexus block.
EU CTIS ID: 2023-506062-31-00
What this study is testing
To look at the efficacy of different doses of perineural dexmedetomidine to prolong the length of the analgetic block after a interscalene plexus block.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients scheduled for elective shoulder surgery
You likely can't join if
- Chronic pain
- Contra-indications for peripheral nerve block
- Allergy for ropivacaine, dexmedetomidine or dexamethasone
- > 80 years old
- second degree AV block
- pregnancy
See the full eligibility criteria
- Patients scheduled for elective shoulder surgery
- Chronic pain
- Contra-indications for peripheral nerve block
- Allergy for ropivacaine, dexmedetomidine or dexamethasone
- > 80 years old
- second degree AV block
- pregnancy
- Emergency operations
- No informed consent
- Medical history of cardial, renal or hepatic failure
- Ethylisme
- Cachexia
- Dehydratation
- Neurologic deficits or neuropathia of the brachial plexus
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.